X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will fund company's research and development efforts primarily focused on advancing its lead candidate, DCCR (diazoxide choline) tablets for the treatment of PWS, through late-stage clinical development, regulatory approval and market development activities.
Lead Product(s): Diazoxide
Therapeutic Area: Genetic Disease Product Name: DCCR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Guggenheim Securities
Deal Size: $69.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 02, 2023
Details:
The proceeds will fund company's research and development efforts primarily focused on advancing its lead candidate, DCCR (diazoxide choline) tablets for the treatment of PWS, through late-stage clinical development, regulatory approval and market development activities.
Lead Product(s): Diazoxide
Therapeutic Area: Genetic Disease Product Name: DCCR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adage Capital Partners LP
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 28, 2023
Details:
The proceeds will fund company's research and development efforts primarily focused on advancing its lead candidate, DCCR (diazoxide choline) tablets for the treatment of PWS, through late-stage clinical development, regulatory approval and market development activities.
Lead Product(s): Diazoxide
Therapeutic Area: Genetic Disease Product Name: DCCR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Guggenheim Securities
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering September 27, 2023
Details:
DCCR is a novel, proprietary extended-release dosage form containing the crystalline salt of (diazoxide choline), which is being investigated for prader-willi syndrome.
Lead Product(s): Diazoxide
Therapeutic Area: Genetic Disease Product Name: DCCR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
DCCR is a novel, proprietary extended-release dosage form containing the crystalline salt of (diazoxide choline), which is being investigated for prader-willi syndrome.
Lead Product(s): Diazoxide
Therapeutic Area: Genetic Disease Product Name: DCCR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
DCCR is a novel, extended-release dosage form containing crystalline salt of diazoxide (diazoxide choline). Diazoxide, has been used for decades in a few rare diseases in neonates, infants, children and adults. It is being developed for prader-willi syndrome.
Lead Product(s): Diazoxide
Therapeutic Area: Genetic Disease Product Name: DCCR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Details:
DCCR (diazoxide choline) is a novel, proprietary extended-release dosage form containing the crystalline salt of diazoxide and is administered once-daily as extended-release tablets for the treatment of Prader-Willi syndrome (PWS).
Lead Product(s): Diazoxide
Therapeutic Area: Genetic Disease Product Name: DCCR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nantahala Capital Management
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Agreement December 19, 2022
Details:
DCCR (Diazoxide Choline) Extended-Release Tablet, is a novel, proprietary extended-release dosage form containing the crystalline salt of diazoxide and is administered once-daily.
Lead Product(s): Diazoxide
Therapeutic Area: Genetic Disease Product Name: DCCR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
DCCR (Diazoxide Choline) Extended-Release Tablets, a novel, proprietary extended-release dosage form containing the crystalline salt of diazoxide and is administered once-daily in treatment of patients with PWS.
Lead Product(s): Diazoxide
Therapeutic Area: Genetic Disease Product Name: DCCR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Folia Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2022
Details:
Patients demonstrated statistically significant improvements in several hormonal and cardiometabolic parameters following treatment with DCCR, (Diazoxide Choline) Extended-Release Tablets.
Lead Product(s): Diazoxide
Therapeutic Area: Genetic Disease Product Name: DCCR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
